Distribution of 67Ga-DOTA-Biotin 24 Hours After Injection Following Pretargeting with scFv-CC49-Streptavidin and Lysine Treatment
| Tissue | Lysine | Control |
|---|---|---|
| Tumor | 1.39 ± 0.086 | 2.36 ± 0.57 |
| Blood | 0.055 ± 0.00066 | 0.036 ± 0.016 |
| Heart | 0.053 ± 0.015 | 0.073 ± 0.038 |
| Liver | 0.41 ± 0.0089 | 0.28 ± 0.0013 |
| Spleen | 0.19 ± 0.044 | 0.14 ± 0.013 |
| Kidney | 1.82 ± 0.59 | 1.17 ± 0.15 |
| Stomach | 0.10 ± 0.0059 | 0.066 ± .0030 |
| Small intestine | 0.10 ± 0.0071 | 0.076 ± 0.013 |
| Large intestine | 0.097 ± 0.025 | 0.083 ± 0.017 |
| Muscle | 0.033 ± 0.0046 | 0.020 ± 0.0027 |
| Bone | 0.053 ± 0.0015 | 0.086 ± 0.037 |
No significant differences between groups. Data are expressed as mean %ID/g tissue ± SD; average animal weight = 25.55 ± 1.23 g; average tumor weight = 171 ± 54 mg. One group was treated intraperitoneally with 4 × 10 mg l-lysine ethyl ester (at time = −10 min, 1 h, 2 h, and 3 h after administration of scFv-CC49-streptavidin); control group received NaCl instead of lysine. Mice were sacrificed 24 h after injection of 67Ga-DOTA-biotin (6.90 ± 0.09 MBq [186.5 ± 2.3 μCi]).